Mutations in progranulin gene (*GRN*) are associated with familial forms of frontotemporal dementia (FTD). The majority of mutations cause haploinsufficiency and are associated with an extremely heterogeneous clinical presentation ([@bib17]) and TAR DNA--binding protein-43 pathology ([@bib9]). Progranulin displays anti-inflammatory properties but can also undergo cleavage to produce granulins, which, conversely, have proinflammatory properties ([@bib14]). Abnormalities of several cytokines and chemokines has been observed in cerebrospinal fluid (CSF) of *GRN* carriers compared with controls ([@bib5]), suggesting an imbalance of specific inflammatory factors possibly related to *GRN* haploinsufficiency.

Previous studies have demonstrated that patients with null mutations in *GRN* display very low plasma progranulin levels compared with sporadic FTD ([@bib3], [@bib6], [@bib13]), and that this analysis is useful to identify carriers of mutation causing haploinsufficiency, independent of the clinical presentation ([@bib1]). A multicenter Italian study, carried out among subjects attending to a memory clinic, suggested a cutoff level of 61.55 ng/mL, which was able to identify null mutation carriers with a sensitivity of 95.8% and a specificity of 99.6% ([@bib7]). Despite its promising role as a biomarker for predicting the presence of a mutation and thus avoiding sequencing, which is expensive and time consuming, caution should be taken in using plasma progranulin levels to predict changes in the brain. In fact, progranulin levels are differently regulated in plasma and CSF, therefore peripheral levels may not adequately represent progranulin levels in the central nervous system ([@bib10], [@bib16]).

Recently, it has been demonstrated in the Genetic Frontotemporal Dementia Initiative (GENFI) study that gray matter and cognitive changes can be identified 5--10 years before the expected onset of symptoms in adults at risk of genetic FTD, including a cohort carrying *GRN* mutations ([@bib12]). Brain atrophy in presymptomatic carriers of common FTD mutations, including *GRN*, is affected by both genetic and environmental factors such as *TMEM106B* rs1990622 polymorphism ([@bib4]). This gene has been actually demonstrated to act as a genetic modifier of *GRN* mutations, influencing the age at disease onset and progranulin levels in mutation carriers ([@bib2], [@bib4]). Carriers of 2 copies of the minor allele of rs1990622 have a significantly reduced penetrance or the onset significantly delayed ([@bib4]).

Given these premises, the main aim of this study was to test the sensitivity and specificity of progranulin plasma levels as predictors of the presence of *GRN* null mutations in asymptomatic at risk members of families with known mutations enrolled in GENFI. Additional objectives include the analysis of (1) the *TMEM106B* rs1990622 genotype as a genetic modifier, and (2) the correlation between progranulin plasma levels and cortical gray-matter atrophy in both symptomatic and asymptomatic subjects.

1. Methods {#sec1}
==========

1.1. Study participants {#sec1.1}
-----------------------

Data for this study were drawn from the GENFI multicentre cohort study ([@bib12]). Eight centers participated in this study from the UK, Italy, the Netherlands, Sweden, Portugal, and Canada. Inclusion and exclusion criteria have been previously described ([@bib12]). Local ethics committees approved the study at each site and all participants provided written informed consent. For the aim of the present work, we considered participants from *GRN* families including those who had already developed symptoms as well as their at-risk relatives (which includes both mutation carriers and noncarriers). Samples from 160 Caucasian subjects belonging to 42 families were available, including 19 patients \[11 females and 8 males, mean age (years) at time of inclusion ± standard deviation (SD) 64.3 ± 5.71, range (years): 55--77\]; 64 asymptomatic carriers (43 females and 21 males, mean age ± SD 49.1 ± 11.1, range 26--70), and 77 noncarriers (49 females and 28 males, mean age ± SD 49.6 ± 15.3, range 19--86). In accordance with the Genfi protocol, samples were collected in the morning after an overnight fasting and processed without delay locally, likely avoiding stability issues and intra-individual variations. All subjects underwent a careful recording of demographic data, including years of formal schooling, past medical history, a standardized clinical and neuropsychological assessment, as previously published, and T1-weighted MRI scan for volumetric analysis ([@bib12]). Characteristics of the cohort studied are summarized in [Table 1](#tbl1){ref-type="table"}.Table 1Characteristics of the GENFI cohort of families with *GRN* mutationsPopulationSymptomaticsAsymptomatics at riskNoncarriersN196477Age ± SD (range)64.3 ± 5.71 (55--77)49.1 ± 11.1 (26--70)49.6 ± 15.3 (19--86)Sex (M:F)8:1121:4328:49Mean progranulin plasma levels ± SD (ng/mL)30.5 ± 13.027.7 ± 7.599.6 ± 24.8[^3]

1.2. DNA isolation {#sec1.2}
------------------

Total genomic DNA was isolated from whole blood using a Flexigene Kit (Qiagen, Hildren, Germany), according to the manufacturer instructions. The amount of DNA for each sample was determined by measuring the optical density at 260-nm wavelength using a spectrophotometer (Eppendorf AG, Wesseling-Berzdorf, Germany). DNA samples were aliquoted and stored at −20 °C until use.

1.3. Genotyping {#sec1.3}
---------------

The entire open reading frame including the noncoding exon 0 and exon-intron boundaries of exons 1--12 of the *GRN* gene was sequenced using specific primers (available upon request) on an AB3130 automated sequencer (Applied Biosystems). Chromatogram analysis was carried out using SeqScape software version 2.5 (Applied Biosystem, Foster City, CA, USA). TMEM106B rs1990622 (C/T) single nucleotide polymorphism genotyping was performed according to standard procedures ([@bib11]).

1.4. Plasma sample collection and progranulin level evaluation {#sec1.4}
--------------------------------------------------------------

EDTA blood samples were allowed to sit at room temperature for a minimum of 30 minutes and a maximum of 2 hours, after collection. Separation of the clot was done by centrifugation at 1000--1300 × *g* at room temperature for 15--20 minutes. Plasma was removed and dispensed in aliquots of 400 μL into cryo-tubes. Specimens were stored at −80 °C until use.

Progranulin levels were tested with a specific ELISA kit (Adipogene, Korea), using polyclonal specific antibodies. According to the manufacturer\'s protocol, the test has a 5.1% CV within an assay (intra-assay precision) and 6.4% CV precision between assays (interassay precision). The limit of detection is 32 pg/mL, with an assay range of 0.063--4 ng/mL. The linearity ranges from 93% to 102%.

1.5. Statistical analysis {#sec1.5}
-------------------------

Descriptive statistics, including means and standard deviations, or counts and percentages were calculated. For plasma progranulin levels, 1-way ANOVA with post hoc Dunn\'s test for multiple comparisons was used. The level of statistical significance was set at *p* \< 0.05.

TMEM106B rs1990622 allelic and genotypic frequencies were compared with the Fisher test. The odds ratio was calculated along with its 95% confidence interval.

1.6. Imaging analysis {#sec1.6}
---------------------

Participants underwent volumetric T1-weighted MR imaging on a 3T or 1.5T scanner at sites where 3T was not available, performed usually on the same day as serum sampling but at a maximum of 12 weeks from the time of sample collection ([@bib12]). Only mutation carriers (presymptomatic and symptomatic subjects) were included in the analysis.

Two separate analyses were performed. First, progranulin levels were correlated with defined regions of interest, specifically cortical gray-matter volumes (corrected for total intracranial volume) of the insula, cingulate, frontal, temporal, parietal, and occipital lobes that were generated using a previously described methodology ([@bib12]). Second, a voxel-wise analysis was performed to assess the correlation of progranulin levels with gray-matter intensity: this voxel-based morphometric analysis was implemented using SPM12 (<http://www.fil.ion.ucl.ac.uk/spm>) adjusting for age, gender, total intracranial volume, and MR scanner.

2. Results {#sec2}
==========

Subjects included were members of families with the following *GRN* mutations: D22fs (n = 2), C31fs (n = 3), G35fs (n = 9), S82fs (n = 37), Q125X (n = 16), Q130fs (n = 7), C149fs (n = 5), C157fs (n = 1), Q249X (n = 12), Q257fs (n = 2), T272fs (n = 44), W386X (n = 3), V411fs (n = 3), C416fs (n = 5), C474fs (n = 1), R493X (n = 10).

Mean ± SD levels in patients and asymptomatic carriers were significantly decreased compared with noncarriers (30.5 ± 13.0 and 27.7 ± 7.5 versus 99.6 ± 24.8 ng/mL, respectively, *p* \< 0.00001, [Fig. 1](#fig1){ref-type="fig"}). Considering the threshold of 61.55 ng/mL, the test had a sensitivity (positive test/number of subjects carrying mutations at sequencing) of 98.8% and a specificity (negative test/total subjects without mutations at sequencing) of 97.4% in predicting the presence of a mutation, independent of symptoms.Fig. 1Box and whiskers plot of progranulin plasma levels. The dotted line indicates the proposed threshold (61.55 ng/mL). ^∗^*p* \< 0.001.

No correlations were found between progranulin plasma levels and age or years from expected average age at onset in each family (*p* \> 0.05, data not shown).

The *TMEM106B* rs1990622 status was available in 141 subjects. None of the symptomatic subjects (n = 12) carried the protective *CC* genotype. The mean age at onset was similar in patients carrying the *TT* (n = 6) compared with *TC* (n = 6) carriers (*p* \> 0.05).

No significant differences in plasma progranulin levels were observed after stratifying for the rs1990622 genotype (*p* \> 0.05).

Neither of the imaging analyses showed significant correlations of gray matter with progranulin levels (data not shown).

3. Discussion {#sec3}
=============

These data demonstrate that progranulin plasma levels represent an excellent predictor of the presence of a null *GRN* mutation independent of symptom proximity and brain atrophy. Therefore, besides its suggested use in clinical settings to identify people to be further screened by sequencing, it could be extremely useful in the future to identify potential subjects to be included in preclinical preventive trials to replace progranulin expression. Results shown here confirm those previously obtained in an Italian population ([@bib7]), suggesting that the cutoff of 61.55 ng/mL would be the best threshold to have an optimal sensitivity and specificity for identifying people carrying a *GRN* null mutation. Considering the low cost of the test and the heterogeneity of clinical presentation and age at onset of the disease in *GRN* carriers, this test could be proposed as routine screening among subjects attending memory clinics.

We acknowledge however that progranulin levels are differently regulated in CSF and plasma, and thus it is likely that peripheral levels do not fully reflect the pathogenic cascade ongoing in the central nervous system ([@bib10], [@bib16]). It is worth noting that progranulin dysregulation is more than expected based on the haploinsufficiency disease mechanism, according to which the wild-type allele would be expressed, thus leading to 50% protein production. Although the mechanisms linking progranulin haploinsufficiency with neurodegeneration are not yet understood, our results show that the deregulation of progranulin expression is a very early event during the lifespan of carriers, as very low levels were observed, in presymptomatic individuals, even in the second or third decade of life, that is, long before the mean age at which symptoms appeared in the family and far from the time at which brain atrophy is observed. This result has profound implications regarding the development of tailored treatments for *GRN* mutation carriers, which should prevent the de-regulation of this gene rather than cure the disease once there is evidence of gray matter atrophy and cognitive changes, previously shown to occur 5--10 years before the appearance of symptoms ([@bib12]). So far, in line with the hypothesis that restoring progranulin levels may be an effective therapy, a few clinical trials with compounds able to do this have been carried out in patients but have failed (see [@bib15], for review).

The penetrance of *GRN* mutations is likely influenced by many other genetic factors, primarily the *TMEM106B* genotype. In this regard, although we analyzed a quite small cohort of symptomatic subjects, it is worth underlining that none of the patients were a carrier of the protective rs1990622 *CC* genotype, thus supporting the evidence that this polymorphism acts as a genetic modifier in *GRN* carriers ([@bib2], [@bib4], [@bib8]).

In conclusion, the evaluation of progranulin plasma levels is an excellent predictor of the presence of a null mutation in *GRN* but is instead of poor utility as proximity marker, that is, predicting the development of symptoms and the prognosis. Considering the heterogeneity of clinical phenotypes and age at onset associated with such mutations and that the analysis is not invasive and low cost, it could be introduced as a routine analysis to be carried out in people attending memory clinics to identify subjects to be further studied by sequencing and in the future extended to at-risk individuals for preventive therapies.
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